Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

Fosun Pharma deeply embraces AI, with its self-developed PharmAID Decision Intelligence Platform boosting efficient innovation

Nowadays, artificial intelligence (AI) technology is profoundly reshaping the landscape of the pharmaceutical and healthcare industry. As a global innovation-driven pharmaceutical and healthcare group, Fosun Pharma places great emphasis on the...

Legacy Pharmacy Group (LPG) and Independent Pharmacy Cooperative (IPC) announce a strategic cooperation agreement

Independent Pharmacy Cooperative (IPC), the leading Group Purchasing Organization (GPO) for independent pharmacies nationwide, is thrilled to announce a groundbreaking cooperation agreement with Legacy Pharmacy Group (LPG). This strategic...

Centinel Spine's Match-the-Disc™ prodisc® Cervical Total Disc Replacement System has completed over 10,000 procedures in the U.S

Centinel Spine®, LLC the leading global medical device company focused exclusively on treating cervical and lumbar spinal disease with the most complete and clinically-proven total disc replacement (TDR) technology platform in the world...

Hoth Therapeutics teams up with OnTargetx R&D to further research for the cancer-fighting HT-KIT therapeutic

Hoth Therapeutics, Inc. a biopharmaceutical company dedicated to developing innovative therapies for unmet medical needs, today announced its collaboration with OnTargetx R&D Inc. to advance research for its cancer-fighting therapeutic, HT-KIT....

HOOKIPA Pharma announces the completion of enrollment in its Phase 1b clinical trial evaluating HB-500 for the treatment of HIV

HOOKIPA Pharma Inc. a clinical-stage biopharmaceutical company developing next-generation immunotherapeutics for the treatment of cancer and serious infectious diseases, today announced that enrollment is complete in the Phase 1b clinical trial...

The merger with NLS Pharmaceutics was approved by Kadimastem shareholders

NLS Pharmaceutics Ltd. a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for rare and complex central nervous system disorders, and Kadimastem Ltd. ("Kadimastem") (TASE: KDST), a...

Beacon Therapeutics has been granted FDA Regenerative Medicine Advanced Therapy (RMAT) designation for laru-zova (AGTC-501)

Beacon Therapeutics Holdings Limited a leading ophthalmic gene therapy company with a mission to save and restore the vision of patients with blinding retinal diseases, announced that the U.S. Food and Drug Administration (FDA) has granted...

Artax Biopharma validates AX-158, a first-in-class oral Nck modulator, in phase 2a for autoimmune disease

Artax Biopharma, Inc., a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases, today announces achievement of clinical validation through its Phase 2a clinical trial in psoriasis with fully proprietary...

SeoulTech researchers unveil a novel approach to understanding PFOS-induced neurotoxicity, advancing environmental health studies

The term "omics" refers to the study of entirety of molecular mechanisms happening inside an organism. With the advent of omics technologies like transcriptomics, proteomics, metabolomics, and lipidomics, our understanding of molecular pathways of...

Chromatin Bioscience's synthetic promoter enables EsoBiotec's ESO-T01 CAR-T therapy to progress to clinical trials

Chromatin Bioscience is pleased to announce its ongoing collaboration with EsoBiotec, which has successfully advanced its ESO-T01 in vivo CAR-T candidate into clinical trials. ESO-T01 is the first in vivo B-cell maturation antige. (BCMA) CAR-T...

Matthew Fyfe has been appointed as Chief Scientific Officer as Outrun Therapeutics expands its leadership team

Outrun Therapeutics ("Outrun"), the E3 ligase inhibitor and protein stabilisation specialist, announces the appointment of Matthew Fyfe as its Chief Scientific Officer. Matthew has over 25 years' experience in drug discovery and development across...

Ouro Medicines launches to transform treatment for immune-mediated diseases with innovative therapies

Ouro Medicines, a biotechnology company developing immune reset therapeutics for people living with chronic immune-mediated diseases, today announced its launch with $120 million in funding. The company was founded by Monograph Capital in...

Mediar Therapeutics partners with Lilly to develop a first-in-class WISP1 antibody for idiopathic pulmonary fibrosis

Mediar Therapeutics, Inc., a clinical stage biotechnology company advancing a portfolio of first-in-class therapies designed to halt fibrosis progression, announced a global licensing agreement with Eli Lilly and Company to advance MTX-463 into a...

RiDYMO® develops a cyclic peptide targeting the "undruggable" β-catenin in just two months

In a recent achievement, DP Technology's hit discovery platform RiDYMO® has successfully designed a cyclic peptide targeting β-catenin, a historically "undruggable" protein, in just two months. This innovative AI-driven approach combines advanced...

Cardurion Pharmaceuticals has named Charlotte Newman as Chief Business Officer

Cardurion Pharmaceuticals, Inc. a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of cardiovascular diseases, today announced that Charlotte (Charlie) Newman has joined the company as...

ADC Therapeutics shares promising initial LOTIS-7 trial data on ZYNLONTA® combined with a bispecific antibody for relapsed/refractory DLBCL.

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), announced positive initial data from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy...

Pilatus Biosciences Inc. earns FDA Orphan Drug Designation for PLT012, targeting liver and intrahepatic bile duct cancer

Pilatus Biosciences Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its leading molecule, PLT012, for treating liver and intrahepatic bile duct cancer (HCC/ICCA). Achieved in November...

Biolexis Therapeutics reports positive outcomes for BLX-7006 in an expanded Diet-Induced Obesity (DIO) model study

Biolexis Therapeutics, a leading metabolic drug discovery company focused on improving the lives of patients with chronic metabolic conditions, including obesity, diabetes, and related diseases, announced the successful completion of an expanded...

SciTech Development reveals promising Phase 1A trial results for T-cell non-Hodgkin lymphoma therapy

SciTech Development, a clinical-stage pharmaceutical company focused on advancements in cancer treatment, is excited to share promising updates from its clinical trial of ST-001 nanoFenretinide (ST-001). Preliminary Trial Findings: Preliminary...

Niterra Ventures invests an additional $18M in Neoplas Med GmbH, supporting advancements in innovative cancer therapies

Greifswald-based medical technology pioneer Neoplas Med GmbH is intensifying its strategic collaboration with Niterra Ventures Company, via an $18M capital increase to expand the market further for innovative wound care technology products. With a...